COLORECTAL CANCER METASTATIC
Clinical trials for COLORECTAL CANCER METASTATIC explained in plain language.
Never miss a new study
Get alerted when new COLORECTAL CANCER METASTATIC trials appear
Sign up with your email to follow new studies for COLORECTAL CANCER METASTATIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
AI-Crafted vaccine takes on colorectal cancer in new trial
⭐️ VACCINE ⭐️ Recruiting nowThis early-phase trial tests a personalized cancer vaccine, designed using AI and quantum physics, for people with stage III colorectal cancer that has been surgically removed. The vaccine is given alongside standard chemotherapy and an immunotherapy drug. The main goal is to see…
Matched conditions: COLORECTAL CANCER METASTATIC
Phase: EARLY_PHASE1 • Sponsor: Biogenea Pharmaceuticals Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated May 17, 2026 02:07 UTC
-
New liposomal combo aims to control advanced colorectal cancer
Disease control Recruiting nowThis study tests a new combination of liposomal irinotecan, fluorouracil, and either bevacizumab or cetuximab as a second treatment for people with advanced colorectal cancer that has spread. The goal is to see if this approach can shrink tumors and delay cancer growth. About 100…
Matched conditions: COLORECTAL CANCER METASTATIC
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated May 17, 2026 02:22 UTC
-
Engineered immune cells take on Hard-to-Treat colorectal cancer
Disease control Recruiting nowThis study tests a new treatment using specially engineered immune cells (CAR-NK cells) that target specific markers on colorectal cancer cells. The goal is to see if these cells are safe and can shrink tumors in people with advanced or metastatic colorectal cancer who have run o…
Matched conditions: COLORECTAL CANCER METASTATIC
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated May 17, 2026 02:19 UTC
-
Heat and drugs join forces to fight liver tumors in advanced cancer
Disease control Recruiting nowThis study tests a new approach for people with advanced breast, melanoma, or colorectal cancer that has spread to the liver. Doctors will use a special heat-based procedure to destroy some liver tumors, which may also wake up the immune system. Then they add immunotherapy drugs …
Matched conditions: COLORECTAL CANCER METASTATIC
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 17, 2026 02:07 UTC
-
New registry study aims to improve liver transplant success for colon cancer patients
Disease control Recruiting nowThis study looks at how well different types of liver transplants work for people whose colorectal cancer has spread to the liver and cannot be removed by standard surgery. Researchers will compare living versus deceased donor transplants, whole versus split liver, and one-step v…
Matched conditions: COLORECTAL CANCER METASTATIC
Sponsor: Northwestern University • Aim: Disease control
Last updated May 17, 2026 02:07 UTC
-
Liver-Directed immunotherapy aims to boost Body's cancer fight before surgery
Disease control Recruiting nowThis early-phase study tests whether a new drug, Nelitolimod, can safely boost the immune system's ability to fight colorectal cancer that has spread to the liver. Ten adults will receive the drug directly into the liver through a special catheter before their scheduled surgery. …
Matched conditions: COLORECTAL CANCER METASTATIC
Phase: EARLY_PHASE1 • Sponsor: Northwell Health • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
New drug combo targets Tough-to-Treat colorectal cancer in phase 3 trial
Disease control Recruiting nowThis study tests whether combining two drugs, tunlametinib and vemurafenib, can help people with a specific genetic form of advanced colorectal cancer (BRAF V600E mutation). About 165 adults aged 18 to 70 with metastatic disease will receive the combination to see if it slows can…
Matched conditions: COLORECTAL CANCER METASTATIC
Phase: PHASE3 • Sponsor: Shanghai Kechow Pharma, Inc. • Aim: Disease control
Last updated May 17, 2026 02:05 UTC
-
Lung-Directed chemo during surgery: a new hope for colorectal cancer spread?
Disease control Recruiting nowThis early-phase study tests a technique called In Vivo Lung Perfusion (IVLP) that delivers chemotherapy directly into one lung during surgery to remove lung tumors. The goal is to kill any remaining cancer cells while reducing side effects on the rest of the body. About 10 adult…
Matched conditions: COLORECTAL CANCER METASTATIC
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
New liver chemo pump study lets patients skip hospital trips
Disease control Recruiting nowThis study looks at whether a chemotherapy pump placed in the liver's main blood vessel is safe and practical for people with colorectal cancer or bile duct cancer that has spread to the liver. About 80 participants will get the pump surgically implanted and then choose to have t…
Matched conditions: COLORECTAL CANCER METASTATIC
Phase: PHASE2 • Sponsor: Michael J Cavnar, MD • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for hard-to-treat bowel cancer: combo therapy enters phase 2 trial
Disease control Recruiting nowThis study tests a new drug called TL938 combined with trastuzumab in people with HER2-positive colorectal cancer that has spread or come back and cannot be removed by surgery. About 80 adults who have already tried standard treatments will receive the combination to find the bes…
Matched conditions: COLORECTAL CANCER METASTATIC
Phase: PHASE2 • Sponsor: Suzhou Teligene Ltd. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New immunotherapy combos tested in liver-spread colorectal cancer
Disease control Recruiting nowThis study tests different combinations of immunotherapy drugs (with or without radiation) in people with colorectal cancer that has spread to the liver and who are scheduled for surgery. The goal is to see if these combinations change the immune environment in the liver tumors a…
Matched conditions: COLORECTAL CANCER METASTATIC
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for hard-to-treat colorectal cancer: targeted drug aims to extend life with fewer side effects
Disease control Recruiting nowThis study tests whether the drug regorafenib can help people with a specific type of advanced colorectal cancer (RAS-mutant) who have already tried one treatment. The goal is to see if a less intensive approach can keep the cancer from growing for at least 6 months while maintai…
Matched conditions: COLORECTAL CANCER METASTATIC
Phase: PHASE2 • Sponsor: National Cancer Institute, Naples • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Could a common seizure drug help beat colorectal cancer?
Disease control Recruiting nowThis study is for people with a certain type of advanced colorectal cancer that has not responded well to previous treatments. Researchers want to see if adding valproic acid, a drug usually used for seizures, can make a standard cancer therapy work again. About 130 adults will b…
Matched conditions: COLORECTAL CANCER METASTATIC
Phase: PHASE2 • Sponsor: National Cancer Institute, Naples • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for hard-to-treat colorectal cancer? drug combo enters human trial
Disease control Recruiting nowThis study tests a new drug, isunakinra, added to an existing immunotherapy (pembrolizumab) for people with advanced colorectal cancer that has not responded to standard treatments. The cancer must have certain genetic features (MSS, TMB-H, and KRAS mutation). The goal is to see …
Matched conditions: COLORECTAL CANCER METASTATIC
Phase: PHASE2 • Sponsor: Buzzard Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
Engineered immune cells take on Hard-to-Treat colon cancer
Disease control Recruiting nowThis early-phase study tests a new treatment called CNA3103 for people with metastatic colorectal cancer that has not responded well to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. Th…
Matched conditions: COLORECTAL CANCER METASTATIC
Phase: PHASE1, PHASE2 • Sponsor: Carina Biotech Limited • Aim: Disease control
Last updated May 08, 2026 12:02 UTC
-
New hope for Hard-to-Treat colorectal cancer: triple drug combo under study
Disease control Recruiting nowThis study tests a new drug, ABT-301, combined with two existing cancer drugs (tislelizumab and bevacizumab) in people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to find the safest dose and see if the combination shrinks tu…
Matched conditions: COLORECTAL CANCER METASTATIC
Phase: PHASE1, PHASE2 • Sponsor: Anbogen Therapeutics, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
Mini device implanted in liver tumors could personalize cancer treatment
Knowledge-focused Recruiting nowThis study tests a small device placed inside liver tumors from colorectal cancer to see how they respond to different drugs. Ten adults will have the device implanted a few days before their scheduled liver surgery, then removed with the tumor. The goal is to check if the proced…
Matched conditions: COLORECTAL CANCER METASTATIC
Phase: EARLY_PHASE1 • Sponsor: Northwell Health • Aim: Knowledge-focused
Last updated May 17, 2026 02:07 UTC
-
Scientists hunt for clues to immunotherapy resistance in bowel cancer
Knowledge-focused Recruiting nowThis study is for people with a specific type of advanced colorectal cancer called MSI. It aims to find out why about 20-30% of patients do not respond to the immunotherapy drug pembrolizumab. By studying 600 participants, researchers hope to identify markers that predict resista…
Matched conditions: COLORECTAL CANCER METASTATIC
Sponsor: Federation Francophone de Cancerologie Digestive • Aim: Knowledge-focused
Last updated May 04, 2026 16:22 UTC